5.9M Data Points per Trial; Manual Reviews Are Falling Behind
Clinical trial data volumes have increased by about 11% each year since 2020. Meanwhile, more than six in ten pharmaceutical companies report difficulty managing data overload. Traditional processes require skilled teams to review large datasets manually, often across disconnected systems and study sites.
Consequently, teams may identify important issues days or weeks after data collection. A late review can allow protocol deviations, persistent data-entry delays, or unusual adverse-event reporting patterns to continue. Therefore, the industry now faces a serious question: can periodic review still protect trial integrity at today’s scale?
ICH E6(R3) Raises the Bar; Which Trial Data Needs Immediate Action?
More data does not always create better oversight. Around one-third of the data points collected in Phase II and III studies may not contribute to the primary analysis. As a result, reviewing every item with equal intensity can consume resources without improving patient safety or study quality.
ICH E6(R3) supports a proportionate approach that focuses attention on critical-to-quality data and processes. Real-time analytics can help teams identify those priorities, monitor meaningful risks, and direct reviewers toward information that may affect participant protection or reliable trial results.
Fragmented Trial Systems Hide Risk; Data Integrity Pays the Price
Electronic data capture systems, decentralized trial tools, and site platforms produce information in different structures. Although sponsors can integrate these sources, inconsistent formats and isolated workflows can still create data silos. Therefore, teams may struggle to obtain a stable and decision-ready view of the study.
Advanced analytics platforms can bring operational, clinical, and safety information into centralized dashboards. Moreover, clear visualizations help cross-functional teams detect anomalies earlier, communicate findings faster, and reduce delays before database lock.
Real-Time Analytics Meets RBQM; Sponsors Can Spot Trial Risks Earlier
Real-time and near-real-time analytics can strengthen risk-based quality management by showing where intervention matters most. Automated alerts may identify protocol violations, inconsistent data, delayed entry, or unexpectedly low adverse-event reporting.
In addition, heatmaps and centralized monitoring can reveal sites that differ from expected performance. Clinical teams can then direct resources toward higher-risk locations instead of applying the same level of review everywhere. This approach supports faster action while maintaining proportionate oversight.
Faster Dashboards, Unreliable Data; Speed Cannot Protect Trial Quality
Real-time access creates value only when the underlying data remains consistent, clinically meaningful, and trustworthy. Sponsors must confirm that analytical systems produce reliable outputs, integrate data correctly, and support controlled decision-making. Otherwise, faster dashboards may simply expose poor-quality information more quickly.
This means sponsors must treat platform governance, validation evidence, access controls, supplier oversight, and ongoing performance review as core parts of clinical quality management rather than as separate technical activities.
Zamann Pharma’s Digital Solutions for GMP-Regulated Operations service supports compliant, efficient digital workflows and computerized systems across regulated pharmaceutical operations. Teams planning connected analytics or data-management environments can explore this support to strengthen data integrity, system control, and scalable digital oversight before implementation.
Source: Pharmexec.Com